These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 11473654

  • 1. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats.
    Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE.
    Kidney Int; 2001 Aug; 60(2):715-21. PubMed ID: 11473654
    [Abstract] [Full Text] [Related]

  • 2. Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat.
    Kubota E, Dean RG, Hubner RA, Casley DJ, Johnston CI, Burrell LM.
    Clin Sci (Lond); 2003 Sep; 105(3):339-45. PubMed ID: 12741953
    [Abstract] [Full Text] [Related]

  • 3. Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats.
    Mifsud SA, Burrell LM, Kubota E, Jaworski K, Cooper ME, Wilkinson-Berka JL.
    Clin Exp Hypertens; 2004 Jan; 26(1):69-80. PubMed ID: 15000298
    [Abstract] [Full Text] [Related]

  • 4. Antihypertensive and antihypertrophic effects of omapatrilat in SHR.
    Burrell LM, Droogh J, Man in't Veld O, Rockell MD, Farina NK, Johnston CI.
    Am J Hypertens; 2000 Oct; 13(10):1110-6. PubMed ID: 11041166
    [Abstract] [Full Text] [Related]

  • 5. Role of Angiotensin-converting enzyme and neutral endopeptidase in flow-dependent remodeling.
    Korshunov VA, Massett MP, Carey RM, Berk BC.
    J Vasc Res; 2004 Oct; 41(2):148-56. PubMed ID: 15004434
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
    Raasch W, Dominiak P, Dendorfer A.
    J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertension.
    Quaschning T, Hocher B, Ruhl S, Kraemer-Guth A, Tilgner J, Wanner C, Galle J.
    Kidney Blood Press Res; 2006 Aug; 29(6):351-9. PubMed ID: 17139187
    [Abstract] [Full Text] [Related]

  • 10. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
    Pu Q, Larouche I, Schiffrin EL.
    Am J Hypertens; 2003 Nov; 16(11 Pt 1):931-7. PubMed ID: 14573331
    [Abstract] [Full Text] [Related]

  • 11. Renal effects of omapatrilat and captopril in salt-loaded, nitric oxide-deficient rats.
    Ying L, Flamant M, Vandermeersch S, Boffa JJ, Chatziantoniou C, Dussaule JC, Chansel D.
    Hypertension; 2003 Nov; 42(5):937-44. PubMed ID: 14569001
    [Abstract] [Full Text] [Related]

  • 12. Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406.
    Sulpizio AC, Pullen MA, Edwards RM, Louttit JB, West R, Brooks DP.
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1306-13. PubMed ID: 16144980
    [Abstract] [Full Text] [Related]

  • 13. In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor.
    Azizi M, Massien C, Michaud A, Corvol P.
    Hypertension; 2000 Jun; 35(6):1226-31. PubMed ID: 10856268
    [Abstract] [Full Text] [Related]

  • 14. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC.
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [Abstract] [Full Text] [Related]

  • 15. Beneficial and adverse renal and vascular effects of the vasopeptidase inhibitor omapatrilat in renovascular hypertensive rats.
    Wenzel UO, Wolf G, Jacob I, Schwegler C, Qasqas A, Amann K, Helmchen U, Stahl RA.
    Nephrol Dial Transplant; 2003 Oct; 18(10):2005-13. PubMed ID: 13679474
    [Abstract] [Full Text] [Related]

  • 16. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.
    Jandeleit-Dahm K, Lassila M, Davis BJ, Candido R, Johnston CI, Allen TJ, Burrell LM, Cooper ME.
    J Hypertens; 2005 Nov; 23(11):2071-82. PubMed ID: 16208151
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
    Regamey F, Maillard M, Nussberger J, Brunner HR, Burnier M.
    Hypertension; 2002 Sep; 40(3):266-72. PubMed ID: 12215465
    [Abstract] [Full Text] [Related]

  • 20. Effects of omapatrilat on blood pressure and renal injury in L-NAME and L-NAME plus DOCA-treated rats.
    Rodriguez-Gomez I, Wangensteen R, Atucha NM, O'Valle F, Del Moral RG, Garcia-Estañ J, Vargas F, Osuna A.
    Am J Hypertens; 2003 Jan; 16(1):33-8. PubMed ID: 12517680
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.